Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai Patents (Class 514/183)
  • Patent number: 11684601
    Abstract: Methods are provided for the treatment of cancer by administering a combination of metabolic interventions to differentiate the cancer cells. The effect on the targeted cancer cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: June 27, 2023
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jiangbin Ye, Yang Li
  • Patent number: 11655455
    Abstract: Provided herein are enhanced systems for potentiating cell-mediated oncolytic viral therapy. Also provided are modified viruses for such systems, and methods of treatment of cancers by administering such systems.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: May 23, 2023
    Assignee: Calidi Biotherapeutics, Inc.
    Inventors: Antonio Fernandez Santidrian, Duong Hoang Nguyen, Dobrin Draganov
  • Patent number: 11654135
    Abstract: Disclosed herein are compositions and methods for treating cancer in a subject. In some embodiments, the methods involve generating an immune response in an individual by inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells. In one embodiment, a method of treating cancer in a subject includes administering amlexanox in combination with immune modulators, such as checkpoint inhibitors, immune co-stimulatory molecules, TLR agonists, and TNFR superfamily agonists. In one embodiment, the checkpoint inhibitors are selected from antibodies against PD-1, PD-L1, and CTLA-4.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: May 23, 2023
    Assignee: Moonshot Pharma LLC
    Inventor: Angela Christiano
  • Patent number: 11623915
    Abstract: Provided herein are novel lipase inhibitors and methods for using the same to treat inflammation, multisystem organ failure, necrotic pancreatic acinar cell death, acute pancreatitis, sepsis (e.g., culture negative sepsis), burns, and acne. For example, provided herein are two novel lipase inhibitors useful in the methods described herein: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 20, 2022
    Date of Patent: April 11, 2023
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Vijay P. Singh, Sampath-Kumar Anandan, Kevin Greenman, Zeeshan Kamal
  • Patent number: 11607125
    Abstract: A method for non-invasive assessment of photoreceptor function in a mammalian subject comprises exposing a subject's eye to a visible light stimulus to initiate an intrinsic reflectance response in one or a population of photoreceptors and capturing multiple images of photoreceptor's intrinsic reflectance response to the stimulus. Patterns of variability in the intrinsic reflectance response of a single photoreceptor or population of photoreceptors are useful in diagnosis and treatment monitoring of an ocular condition, disease, disorder or a response to treatment for said ocular condition, disease or disorder.
    Type: Grant
    Filed: April 20, 2019
    Date of Patent: March 21, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Jessica I. W. Morgan, David H. Brainard, Robert F. Cooper, William S. Tuten
  • Patent number: 11578055
    Abstract: Provided herein are triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same. For example, provided herein are compounds of Formula (I) and pharmaceutically acceptable salts and compositions including the same. The compounds disclosed herein may be used, for example, in the treatment of diseases including inflammation and/or cancer.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: February 14, 2023
    Assignee: KEZAR LIFE SCIENCES
    Inventor: Henry Johnson
  • Patent number: 11572393
    Abstract: Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: February 7, 2023
    Assignees: THE UNIVERSITY OF TOKYO, ONO PHARMACEUTICAL CO., LTD., TOKYO UNIVERSITY OF SCIENCE FOUNDATION
    Inventors: Kouji Matsushima, Satoshi Ueha, Shungo Deshimaru, Chang-Yu Chen, Shoji Yokochi, Yoshiro Ishiwata, Shiro Shibayama
  • Patent number: 11559231
    Abstract: A method and system is provided for determining a discrimination index in a subject that may be suffering from or at risk for a stress-induced psychiatric disorder. The discrimination index may be equal to a ratio of a subject's cued fear response and non-cued fear response measured during a fear-potentiated startle (FPS) paradigm. Such a value may allow a physician or researcher to quantify how well a subject discriminates between signaled (cued) fear and un-signaled (non-cued) fear, which may be a biomarker for psychiatric disorders like post-traumatic stress disorder, panic disorder, phobias, and/or generalized anxiety disorder. The determined discrimination index may provide a standardized way of diagnosing and evaluating mental illnesses, more uniform treatment of patients, and/or more precise monitoring and evaluation of treatment efficacy.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: January 24, 2023
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventor: Joanna Dabrowska
  • Patent number: 11555185
    Abstract: The present disclosure provides, among other things, a way to amplify and sequence target sequences in a low-input sample. In some embodiments, the method comprises ligating a double-stranded adaptor onto a population of fragments to produce tagged fragments, and linearly amplifying the tagged fragments.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: January 17, 2023
    Assignee: New England Biolabs, Inc.
    Inventors: Cynthia Hendrickson, Sarah Bowman, Amy Emerman, Kruti Patel
  • Patent number: 11554115
    Abstract: The present invention provides a quinoline derivative for treating triple-negative breast cancer and use thereof in preparing a pharmaceutical composition for treating a tumor.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: January 17, 2023
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Xin Tian, Peng Lv, Ling Yang, Xiangjian Wang, Xiquan Zhang, Shanchun Wang, Xunqiang Wang, Hai Jiang
  • Patent number: 11530204
    Abstract: The disclosure provides cryptophycin intermediates, cryptophycin analogs, and cryptophycin chimeric molecules useful in treating cancer, as well as methods of producing these compounds and methods of treating cancer.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: December 20, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: David H. Sherman, Jennifer J. Schmidt
  • Patent number: 11523772
    Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an immunosuppressant.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: December 13, 2022
    Assignee: BIORA THERAPEUTICS, INC.
    Inventors: Mitchell Lawrence Jones, Sharat Singh, Christopher Loren Wahl, Harry Stylli
  • Patent number: 11505782
    Abstract: Provided herein are carrier cells and virus combinations and methods for treatment of cancers. Also provided are modified carrier cells for such treatment, and methods of selecting carrier cells that are matched to subjects for such treatment.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: November 22, 2022
    Assignee: Calidi Biotherapeutics, Inc.
    Inventors: Dobrin Draganov, Aladar A. Szalay
  • Patent number: 11464784
    Abstract: The current methods and compositions provide for therapeutic approaches to treating hepatocellular carcinoma (HCC) and other types of cancer including, for example, pancreatic and colon cancer. Accordingly, certain aspects of the disclosure relates to methods and compositions for treating HCC, pancreatic and colon cancer using one or more small molecule inhibitors disclosed herein. In certain embodiments, the small molecule inhibitor is a benzothiazine, a sulfonamide, a thiazolidinone or other chemical compound.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: October 11, 2022
    Assignee: The Regents of the University of California
    Inventors: Ira B Kurtz, Alexander Pushkin, Kirill B. Tsirulnikov
  • Patent number: 11464757
    Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: October 11, 2022
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Patent number: 11439618
    Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: September 13, 2022
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Patent number: 11434237
    Abstract: The invention provides compounds of formula (I) and compositions comprising compounds of formula (I). The invention further provides uses of the compounds of formula (I) and compositions comprising compounds of formula (I), including the use of such compounds for the detection of tau deposits, and the use of such compounds and compositions as diagnostic agents in the diagnosis or monitoring of the progression of a disease or disorder such as Alzheimer's disease or corticobasal degeneration, or for the prevention or treatment of a disease or disorder such as Alzheimer's disease or corticobasal degeneration.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: September 6, 2022
    Assignee: KARIN & STEN MORTSTEDT CBD SOLUTIONS AB
    Inventors: Peter Nilsson, Hamid Shirani
  • Patent number: 11433048
    Abstract: The invention relates to a CXCR4 receptor-binding compound for use for increasing or restoring interferon (IFN) level in an individual, wherein the interferon is a type-I interferon (IFN-I).
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: September 6, 2022
    Inventors: Nicolas Pietrancosta, Nikaïa Smith, Jean-Philippe Herbeuval
  • Patent number: 11396525
    Abstract: Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such as for inducing sedation and/or anesthesia.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: July 26, 2022
    Assignee: Sage Therapeutics, Inc.
    Inventors: Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Francesco G. Salituro, Andrew Griffin, Maria Jesus Blanco-Pillado
  • Patent number: 11371099
    Abstract: The present invention relates to methods of using HEATR1 expression levels for guiding chemotherapy treatment of pancreatic cancer. In particular, measuring lower HEATR1 expression in pancreatic cancer is associated with resistance to the use of certain chemotherapy treatments such that by changing the treatment a better prognosis may be obtained for the patient. Further, lower HEATR1 expression is related to a poorer long-term prognosis of pancreatic cancer patients thus measuring an increase or maintenance/decrease during treatment may be useful for predicting treatment response.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: June 28, 2022
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Zhenkun Lou, Tongzheng Liu
  • Patent number: 11365183
    Abstract: The present invention provides compounds (n-3 PUFA derivatives) of formula (I): that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: June 21, 2022
    Assignees: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN, BOARD OF REGENTS OF UNIVERSITY OF TEXAS SYSTEM
    Inventors: Wolf-Hagen Schunck, Gerd Wallukat, Robert Fischer, Cosima Arnold, Dominik N. Mueller, Narender Puli, John R. Falck
  • Patent number: 11364203
    Abstract: Disclosed are processes for forming compositions comprising small domains of an active agent and a matrix material, and methods of using them. A suspension of an active agent, a matrix material, a first solvent, and a second solvent is formed at a temperature T1, heated to a temperature T2 and spray dried.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: June 21, 2022
    Assignee: Bend Reserch, Inc.
    Inventors: David Thomas Vodak, Dwayne Thomas Friesen
  • Patent number: 11351187
    Abstract: Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: June 7, 2022
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Clive Arthur Arculus-Meanwell, Simona Skerjanec, Jayne Prats
  • Patent number: 11339126
    Abstract: Provided herein are novel lipase inhibitors and methods for using the same to treat inflammation, multisystem organ failure, necrotic pancreatic acinar cell death, acute pancreatitis, sepsis (e.g., culture negative sepsis), burns, and acne. For example, provided herein are two novel lipase inhibitors useful in the methods described herein: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: May 24, 2022
    Assignees: Mayo Foundation for Medical Education and Research, Nanosyn, Inc.
    Inventors: Vijay P. Singh, Sampath-Kumar Anandan, Kevin Greenman, Zeeshan Kamal
  • Patent number: 11338140
    Abstract: Provided herein are methods, devices, compositions, and kits for monitoring neuromodulation efficacy based on changes in the level or activity of one or more target biomarkers. One aspect includes a comparison of baseline and post-modulation levels of one or more biomarkers in bodily fluid that have each been collected from a human subject at a relevant time, and that may be used to assess the neuromodulation efficacy. The post-neuromodulation levels for the one or more biomarkers may be collected from the human subject within about 5 minutes to about 14 days post-neuromodulation.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: May 24, 2022
    Assignee: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
    Inventors: Ayala Hezi-Yamit, Rudy Beasley, Susan Edwards, Lori Garcia, Michele Lee Silver, Christopher W. Storment, Carol M. Sullivan, Joseph A. Traina, Stefan Stoyanov Tunev
  • Patent number: 11278521
    Abstract: Provided herein are compounds that can bind GAS5 long non-coding RNA, compositions thereof, and uses thereof.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: March 22, 2022
    Assignees: UNIVERSITY OF SOUTH FLORIDA, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS OFFICE OF GENERAL COUNSEL—PSG IV (024)
    Inventors: Niketa A. Patel, Jianfeng Cai
  • Patent number: 11273151
    Abstract: The present invention relates to methods of treating a tumor or treating cancer in a subject having a p53 DNA contact mutation that involve administering, to the subject, a ROCK inhibitor. Also disclosed is a method of identifying a subject as a candidate for such treatment.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: March 15, 2022
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Stuart Aaronson, Albino Troilo, Davide Esposito
  • Patent number: 11274110
    Abstract: A process for preparing the benzothiophen-2-yl boronate of formula (VI) which serves as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of proliferative disorders, such as cancer and tumor diseases.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: March 15, 2022
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Jörg Gries, Johannes Platzek
  • Patent number: 11248001
    Abstract: The invention relates to novel heteroaryl compounds of Formula (I) and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using the novel heterocyclic compounds disclosed herein.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: February 15, 2022
    Assignee: AstraZeneca AB
    Inventors: Michael H. Serrano-Wu, Mark Chambers, Erica Goldsmith, Jason Tierney, Karamjit Jandu, David Clark, Paul Hinchliffe
  • Patent number: 11234954
    Abstract: Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle. Also, the dosages described herein are safe for elderly individuals.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: February 1, 2022
    Assignee: Currax Pharmaceuticals LLC
    Inventors: Roberta L. Rogowski, Susan Ellen Dube, Philip Jochelson, Neil Barton Kavey
  • Patent number: 11214553
    Abstract: Disclosed is a method for preparing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) of formula (II), comprising the following steps: carrying out an alkylation reaction on cyclen in formula (I) and XCH2COOR in the presence of an acid-binding agent in water; adjusting a pH value to separate out a crude product of DOTA; and recrystallizing. The preparation method of the present invention is applicable to large-scale industrial production of DOTA, the whole process does not need to adopt an ion-exchange resin or low-temperature refrigeration mode for purification, and the purity and yield of the product are higher.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: January 4, 2022
    Assignee: VIWIT PHARMACEUTICAL CO., LTD.
    Inventors: Zhoujun Meng, Yigang He, Yanjun Wei, Yanping Xing
  • Patent number: 11208396
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (I) where p; q; X1; X2; Y; R1; R2; R3; R4; R5 and R6 are as defined herein.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: December 28, 2021
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Benjamin Gerald Tehan
  • Patent number: 11203601
    Abstract: The present disclosure provides compounds of Formula (I), and salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be useful for inhibiting kinases, e.g., glycogen synthase kinase 3 (GSK3). The provided compounds may be able to selectively inhibit GSK3a, as compared to GSK3P and/or other kinases. The present disclosure further provides pharmaceutical compositions, kits, and methods of use, each of which involve the compounds. The compounds, pharmaceutical compositions, and kits may be useful for treating diseases associated with aberrant activity of GSK3a (e.g., Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder).
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: December 21, 2021
    Assignees: The Broad Institute, Inc., Biogen MA Inc.
    Inventors: Florence Fevrier Wagner, Michel Weiwer, Arthur J. Campbell, Joshua R. Sacher, Edward Holson, Brian Stuart Lucas, TeYu Chen
  • Patent number: 11186544
    Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: November 30, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nicholas R. Wurtz, Pravin Sudhakar Shirude, Andrew Quoc Viet
  • Patent number: 11186588
    Abstract: The 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivatives or salts thereof of the present invention have BRD4 inhibitory activity, and thus, they are useful as medicaments, in particular, as prophylaxis and/or therapeutic agents for diseases associated with BRD4.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: November 30, 2021
    Assignee: AYUMI PHARMACEUTICAL CORPORATION
    Inventors: Hiroyuki Aono, Iwao Seki, Miwa Imamura, Tomomi Tanaka, Satoshi Shirae, Kenji Kawashima, Yusuke Yamazaki, Minoru Yamamoto
  • Patent number: 11154543
    Abstract: Methods of the invention treat, reduce, or reverse fibrosis of a bodily tissue by administering to the local affected tissue a composition comprising an inhibitor of p38 MAP kinase, which treatment leads to a reduction or reversal of fibrosis.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: October 26, 2021
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Xiaoqing Guo, James D. Zieske
  • Patent number: 11154525
    Abstract: The present invention refers to new purified compositions of long chain polyunsaturated fatty acids, or their salts or esters, characterized by being essentially free from other usually present—but structurally different—components, such as furan fatty acids, phytanic and pristanic acids, squalene, and some oligomers, as well as several “persistent” environmental pollutants, such as polychlorinated dibenzo-dioxins and polychlorinated dibenzo-furans, polychlorinated biphenyls, polybrominated diphenyl-ethers, polycyclic aromatic hydrocarbons, and others, which are also usually present and extremely toxic. The invention also refers to the purification method to obtain said compositions and the use thereof as food, food for special medical use, food and diet supplement, and drug.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: October 26, 2021
    Inventor: Tiberio Bruzzese
  • Patent number: 11154558
    Abstract: The use of direct factor Xa inhibitors, administered in a dose sufficient to reduce the activity of factor Xa to about 25% less than normal or lower, has the effect of preventing the onset of atherosclerosis, and stabilizing atherosclerotic lesions, and preventing the occurrence or recurrence of atherosclerotic events.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: October 26, 2021
    Assignee: Adams Pharmaceuticals LLC
    Inventors: Jonathan Adams, Peter Jeffrey Adams
  • Patent number: 11154712
    Abstract: Provided herein are methods, devices and compositions for assessing neuromodulation efficacy based on changes in the level of one or more biomarkers in plasma or urine collected from a human subject following a renal neuromodulation procedure.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: October 26, 2021
    Assignee: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
    Inventors: Carol Sullivan, Stefan Tunev
  • Patent number: 11155551
    Abstract: Derivatives of N,N-diethyl-N?-phenyl-piperazine, a silent agonist of the mammalian ?7 nicotinic acetylcholine receptor, are provided. These silent agonists control the desensitization state of the receptor. Further provided are pharmaceutical compositions that allow the administration of the silent agonists of the disclosure to a subject animal or human in need of treatment for a pathological condition arising from such as inflammation. The novel silent agonists also may be co-administered to a patient simultaneously or consecutively with a type II positive allosteric modulator to modulate the activity of the receptor.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: October 26, 2021
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Nicole Alana Horenstein, Roger Lee Papke, Marta Quadri
  • Patent number: 11147810
    Abstract: The present invention provides pharmaceutical composition of antineoplastic alkylating agent in oral suspension dosage form. The oral suspension composition comprises of alkylating agent with other pharmaceutical excipients such as vehicle, preservative, antioxidant, suspending agent, surfactant, sweetener and flavouring agent. The present invention is an oral suspension having improved stability and palatability. The present invention also provides oral solution with flavor that has masked bitter taste of the drug. Further, the present invention also provides a process for preparation thereof.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: October 19, 2021
    Assignee: FTF PHARMA PRIVATE LIMITED
    Inventors: Sandip Mehta, Manish Umrethia, Henil Patel, Jayanta Kumar Mandal
  • Patent number: 11142511
    Abstract: The present invention relates to a coumarin (keto) oxime ester compound of formula (I), wherein n and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification. The compound has strong ultraviolet absorption in the range of 300 to 450 nm. After absorbing light energy, it can quickly transfer energy and continuously initiate polymerization. It has obvious advantages in terms of photosensitivity and pattern integrity, and is very suitable for radiation curing by UV-LED light source. In addition, the compound of formula (I) also has good thermal stability. The present invention also relates to a method for preparing the compound of formula (I) and use of the compound. The compound is suitable as a photoinitiator in a UV-LED light curing system and is suitable for the radiation wavelength of UV-LED light curing.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: October 12, 2021
    Assignee: Hubei Gurun Technology Co., Ltd.
    Inventors: Yulian Pang, Yingquan Zou, Shuheng Fan, Ming Gao, Yangyang Xin
  • Patent number: 11136327
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: October 5, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: James R. Corte, Tianan Fang, Carl P. Decicco, Donald J. P. Pinto, Karen A. Rossi, Zilun Hu, Yoon Jeon, Mimi L. Quan, Joanne M. Smallheer, Yufeng Wang, Wu Yang
  • Patent number: 11103497
    Abstract: The present invention provides 4-anilino-3-quinolinecarbonitriles compounds useful for treating a subject having an BcrAbl positive leukemia that is resistant to imatinib.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: August 31, 2021
    Assignee: Wyeth LLC
    Inventor: Becker Hewes
  • Patent number: 11083795
    Abstract: The invention provides an amorphous metal-organic framework for use in methods of treatment. The amorphous metal-organic framework may hold a component for delivery. The amorphous metal-organic framework is obtained or is obtainable by amorphization of a crystalline amorphous metal-organic framework holding the component. The amorphous metal-organic framework may be a zirconium-containing or a bismuth-containing metal-organic framework, such as a framework having arylcarboxylate ligands, such as benzenedicarboxylate ligands.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: August 10, 2021
    Assignee: Cambridge Enterprise Limited
    Inventors: Claudia Orellana-Tavra, Nigel Slater, David Fairen-Jimenez, Michelle Teplensky, Emma Baxter, Thomas Bennett, Anthony Cheetham
  • Patent number: 11065235
    Abstract: The present invention relates to substituted methanopyrido [2,1-a]isoindolones of formula I, wherein, R1 is selected from phenylsulfonyl or p-toluenesulfonyl; and n=1, 2, 3; their derivatives, stereoisomers, pharmaceutically acceptable salts and pharmaceutically acceptable compositions having potential muscarinic acetylcholine receptor modulator activity.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: July 20, 2021
    Assignees: Council of Scientific & Industrial Research, Centre for Biomedical Research
    Inventors: Ganesh Pandey, Rajesh Varkhedkar, Divya Tiwari, Prem Narayan Yadav, Shalini Dogra, Yusuf Hussain
  • Patent number: 11052070
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: July 6, 2021
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
  • Patent number: 11046714
    Abstract: The present invention is directed to 2,2-difluorodioxolo compounds that are antagonists of A2A receptor. The present invention is also directed to uses of the 2,2-difluorodioxolo compounds described herein in the potential treatment or prevention of neurological disorders and diseases in which A2A receptor are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds and to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which A2A receptors are involved.
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: June 29, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ali Amjad, Gioconda V. Gallo, Timothy J. Henderson, Rongze Kuang, Yeon-Hee Lim, Michael Man-Chu Lo, Edward Metzger, Manuel de Lera Ruiz, Andrew Stamford, Paul Tempest, Brent Whitehead, Heping Wu
  • Patent number: 11045457
    Abstract: Disclosed are compounds of Formula 1, stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R5, R6, R7, R9, R10, R11, R12, X1, X2, X3, X4, X13, and X14 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: June 29, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Zacharia Cheruvallath, Jason Green, Ben Johnson, Kristin Schleicher, Huikai Sun, Mingnam Tang
  • Patent number: 11040984
    Abstract: Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: June 22, 2021
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Xile Liu, Charles Z. Ding, Shuhui Chen, Lingyun Wu, Lihong Hu, Haiwen Wan